FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2867029644> ?p ?o ?g. }

• W2867029644 endingPage "380" @default.
• W2867029644 startingPage "368" @default.
• W2867029644 abstract "The ligand quantity, ligand type, and coordination geometry have important influences on the anticancer activity of metal-based complexes. On the basis of the structures of previously reported 1:1 Cu(II)/ligand complexes ([Cu(L1)Cl]·2H2O 1a, [Cu(L2)Cl]·H2O 2a, and [Cu(L2)NO3]·H2O 3a), we subsequently designed, developed, and characterized a series of corresponding 1:1:1 Cu(II)/ligand/co-ligand complexes ([Cu(L1)(Py)Cl]·H2O 1b, [Cu(L2)(Py)Cl] 2b, and [Cu(L2)(Py)NO3] 3b), where L1 = (E)-N'-(2-hydroxybenzylidene)acetohydrazide, L2 = (E)-N'-(2- hydroxybenzylidene)benzohydrazide, and Py = pyridine. All six Cu(II) complexes were assessed for their in vitro anticancer properties against a panel of human cancer cells, including cisplatin-resistant A549cisR cell lines. Interestingly, we observed that the 1:1:1 Cu/ligand/co-ligand mixed-ligand Cu(II) complexes exhibited higher anticancer activity than the corresponding 1:1 Cu(II)/ligand complexes. In particular, the 1:1:1 Cu(II)/ligand/co-ligand complex 3b displayed the greatest toxicity toward several cancer cells with better IC50 (1.12-3.77 μM) than cisplatin. Further mechanistic explorations showed that the 3b complex induced DNA damage, thus resulting in mitochondria-mediated apoptotic cell death. Furthermore, the 3b complex displayed pronounced cytostatic effects in the MCF-7 3D spheroid model." @default.
• W2867029644 created "2018-07-19" @default.
• W2867029644 creator A5001016477 @default.
• W2867029644 creator A5011979551 @default.
• W2867029644 creator A5012782087 @default.
• W2867029644 creator A5016373511 @default.
• W2867029644 creator A5016614062 @default.
• W2867029644 creator A5016643073 @default.
• W2867029644 creator A5075613686 @default.
• W2867029644 creator A5076900083 @default.
• W2867029644 date "2018-08-01" @default.
• W2867029644 modified "2023-10-18" @default.
• W2867029644 title "Mixed-ligand Cu(II) hydrazone complexes designed to enhance anticancer activity" @default.
• W2867029644 cites W1169719024 @default.
• W2867029644 cites W1914754028 @default.
• W2867029644 cites W1972779889 @default.
• W2867029644 cites W1984883623 @default.
• W2867029644 cites W1986406178 @default.
• W2867029644 cites W1987167527 @default.
• W2867029644 cites W1998129814 @default.
• W2867029644 cites W2001976945 @default.
• W2867029644 cites W2003177109 @default.
• W2867029644 cites W2005010993 @default.
• W2867029644 cites W2013333371 @default.
• W2867029644 cites W2014474658 @default.
• W2867029644 cites W2015434513 @default.
• W2867029644 cites W2017426705 @default.
• W2867029644 cites W2024100326 @default.
• W2867029644 cites W2024145763 @default.
• W2867029644 cites W2024382973 @default.
• W2867029644 cites W2040527477 @default.
• W2867029644 cites W2044704182 @default.
• W2867029644 cites W2048739939 @default.
• W2867029644 cites W2048969187 @default.
• W2867029644 cites W2054119278 @default.
• W2867029644 cites W2057977480 @default.
• W2867029644 cites W2062621888 @default.
• W2867029644 cites W2065485865 @default.
• W2867029644 cites W2065771556 @default.
• W2867029644 cites W2066916023 @default.
• W2867029644 cites W2071659439 @default.
• W2867029644 cites W2081703161 @default.
• W2867029644 cites W2103789233 @default.
• W2867029644 cites W2104852531 @default.
• W2867029644 cites W2114886506 @default.
• W2867029644 cites W2130237005 @default.
• W2867029644 cites W2145538324 @default.
• W2867029644 cites W2152793164 @default.
• W2867029644 cites W2153383148 @default.
• W2867029644 cites W2157567077 @default.
• W2867029644 cites W2178915615 @default.
• W2867029644 cites W2196668263 @default.
• W2867029644 cites W2203908584 @default.
• W2867029644 cites W2330064972 @default.
• W2867029644 cites W2336403468 @default.
• W2867029644 cites W2344984955 @default.
• W2867029644 cites W2346347666 @default.
• W2867029644 cites W2464668893 @default.
• W2867029644 cites W2473712600 @default.
• W2867029644 cites W2508355060 @default.
• W2867029644 cites W2519985055 @default.
• W2867029644 cites W2525068761 @default.
• W2867029644 cites W2606418943 @default.
• W2867029644 cites W2610648233 @default.
• W2867029644 cites W2610736154 @default.
• W2867029644 cites W2644476668 @default.
• W2867029644 cites W2731789828 @default.
• W2867029644 cites W2741269304 @default.
• W2867029644 cites W2765399091 @default.
• W2867029644 cites W2800665747 @default.
• W2867029644 cites W2912800377 @default.
• W2867029644 cites W2952165521 @default.
• W2867029644 doi "https://doi.org/10.1016/j.ejmech.2018.07.022" @default.
• W2867029644 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30015073" @default.
• W2867029644 hasPublicationYear "2018" @default.
• W2867029644 type Work @default.
• W2867029644 sameAs 2867029644 @default.
• W2867029644 citedByCount "51" @default.
• W2867029644 countsByYear W28670296442018 @default.
• W2867029644 countsByYear W28670296442019 @default.
• W2867029644 countsByYear W28670296442020 @default.
• W2867029644 countsByYear W28670296442021 @default.
• W2867029644 countsByYear W28670296442022 @default.
• W2867029644 countsByYear W28670296442023 @default.
• W2867029644 crossrefType "journal-article" @default.
• W2867029644 hasAuthorship W2867029644A5001016477 @default.
• W2867029644 hasAuthorship W2867029644A5011979551 @default.
• W2867029644 hasAuthorship W2867029644A5012782087 @default.
• W2867029644 hasAuthorship W2867029644A5016373511 @default.
• W2867029644 hasAuthorship W2867029644A5016614062 @default.
• W2867029644 hasAuthorship W2867029644A5016643073 @default.
• W2867029644 hasAuthorship W2867029644A5075613686 @default.
• W2867029644 hasAuthorship W2867029644A5076900083 @default.
• W2867029644 hasConcept C116569031 @default.
• W2867029644 hasConcept C141071460 @default.
• W2867029644 hasConcept C155647269 @default.
• W2867029644 hasConcept C170493617 @default.
• W2867029644 hasConcept C178790620 @default.

• next